Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neuroone Medical Technologies (NMTC) EBIT (2016 - 2025)

Neuroone Medical Technologies' EBIT history spans 14 years, with the latest figure at -$1.7 million for Q4 2025.

  • For Q4 2025, EBIT fell 199.77% year-over-year to -$1.7 million; the TTM value through Dec 2025 reached -$7.6 million, down 12.67%, while the annual FY2025 figure was -$4.2 million, 64.45% up from the prior year.
  • EBIT reached -$1.7 million in Q4 2025 per NMTC's latest filing, down from -$1.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $1.7 million in Q4 2024 to a low of -$3.5 million in Q2 2023.
  • Average EBIT over 5 years is -$2.4 million, with a median of -$2.8 million recorded in 2022.
  • Peak YoY movement for EBIT: skyrocketed 150.47% in 2024, then tumbled 199.77% in 2025.
  • A 5-year view of EBIT shows it stood at -$2.8 million in 2021, then soared by 36.48% to -$1.8 million in 2022, then plummeted by 90.01% to -$3.4 million in 2023, then surged by 150.47% to $1.7 million in 2024, then crashed by 199.77% to -$1.7 million in 2025.
  • Per Business Quant, the three most recent readings for NMTC's EBIT are -$1.7 million (Q4 2025), -$1.4 million (Q3 2025), and -$1.9 million (Q2 2025).